MTOR and neoplasm: As such, recently mTOR inhibitors, which include sirolimus (rapamycin), temsirolimus, and everolimus, have garnered favour because they have a lower association with de novo skin malignancies, and may in-and-of themselves have a direct anti-tumor effect.